Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity. As patients age on therapy for their chronic lymphocytic leukemia (CLL), ...
Former UVA School of Medicine assistant professors Tomasz Cierpicki and Jolanta Grembecka, now at the University of Michigan, say their newly approved leukemia drug is offering hope to patients. “We ...
Crossbow Therapeutics, Inc., a biotechnology company developing a novel class of potent and precise antibody therapies to treat ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced it will ...
VnExpress International on MSN
Vietnamese scientist discovers rice compounds that outperform chemo drugs against blood cancer
La Hoang Anh spent hundreds of failed lab sessions before proving that compounds found in ordinary rice can kill leukemia cells more effectively than some common chemotherapy drugs.
Findings indicate small increases in certain cancers linked to assisted reproduction, though overall cancer incidence aligns ...
Size-exclusion chromatography (SEC) was used to purify extracellular vesicles (EVs) from the plasma of chronic myeloid leukemia (CML) patients to evaluate treatment responses and mutation statuses.
This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoformsNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer ...
The Well News on MSN
Facing higher health care costs in 2026? Here's how to navigate coverage challenges
Health care costs in America can change as quickly as a diagnosis. One month, a treatment is manageable; the next, a coverage shift or a single high bill can make that same care feel out of reach.
In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.
Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc.
Xspray Pharma AB (publ) has re-submitted its application for market approval for Dasynoc® to the U.S. Food and Drug Administration (FDA). Dasynoc® is the company's lead product candidate - an amorphou ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results